Aurobindo gets USFDA nod for sildenafil tablets

摘要

Aurobindo Pharma Ltd. has announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Sildenafil tablets, 20 mg. This product is expected to be launched by Q4 FY 2015-16. The approved ANDA is bioequivalent and therapeutically equivalent to the re- ference listed drug product 'Revatio' (sildenafil citrate) tablets 20 mg of Pfizer, Aurobindo said.